Bgm Group Ltd's

The competitive landscape in China includes several companies manufacturing products similar to those of the WFOE, the VIE, and its subsidiaries. Jiangxi Pharmaceutical Co., Ltd. is noted as the only company producing compound licorice tablets. Competitors for oxytetracycline tablets include Shanxi Datong Tongxing Antibiotics Co., Ltd., Chifeng Pharmaceutical Co., Ltd., and Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. Producers of oxytetracycline active pharmaceutical ingredients (APIs) include Yunnan Baiyao Group Co., Ltd., Kunming Pharmaceutical Group Co., Ltd., Hunan Jianlang Pharmaceutical Co., Ltd., Hainan Pharmaceutical Factory Co., Ltd. No. 2 Pharmaceutical Factory, and Anhui Fengyuan Pharmaceutical Co., Ltd. Gansu QLS differentiates itself by having products approved for human consumption by the China Food and Drug Administration (CFDA), whereas some competitors’ oxytetracycline products are certified only for veterinary use by the Chinese Ministry of Agriculture. Gansu QLS also reports advantages in production metrics such as fermentation unit, fermentation yield, and bacterial infection rate, which contribute to higher production rates, product quality, and scale. The WFOE, the VIE, and its subsidiaries consider their competitive strengths to include their geographic location in West China, unique product combinations, and lower pricing.